TNF Pharmaceuticals, Inc.
TNFA
$0.0641
-$0.011-14.65%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -40.80% | -49.45% | -38.54% | -22.47% | -11.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.60% | -51.80% | -47.07% | -25.43% | -11.44% |
| Operating Income | 37.60% | 51.80% | 47.07% | 25.43% | 11.44% |
| Income Before Tax | 60.90% | -19.50% | -483.98% | -339.60% | -34.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.90% | -19.50% | -483.98% | -339.60% | -34.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.90% | -19.50% | -483.98% | -339.60% | -34.82% |
| EBIT | 37.60% | 51.80% | 47.07% | 25.43% | 11.44% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 74.05% | 22.98% | -124.65% | -150.31% | -4.72% |
| Normalized Basic EPS | 74.52% | 2.80% | -289.62% | -162.66% | 23.74% |
| EPS Diluted | 77.23% | 33.61% | -75.60% | -96.65% | -19.38% |
| Normalized Diluted EPS | 80.28% | 28.06% | -114.90% | -73.01% | 1.50% |
| Average Basic Shares Outstanding | 238.46% | 86.72% | 57.37% | 51.61% | 43.28% |
| Average Diluted Shares Outstanding | 87.65% | -1.95% | -21.86% | -27.75% | 158.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.27% | 0.59% | 0.69% | -- | -- |